Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

Local AngⅡ Levels and Extracellular Signal-Regulated Kinase Activation in Splenic Vein Vasculopathy in Portal Hypertension

[Laparoscopic Splenectomy and Pericardial Devascularization for Treatment of Portal Hypertension Due to Liver Cirrhosis].

Laparoscopic splenectomy plus pericardial devascularization for the treatment of portal hypertension in cirrhotic patients

Mo1891 KLF2 Function on the Pathological Angiogenesis in Patients of Cirrhosis-Induced Portal Hypertension

Portal Vein Thrombosis Can Aggravate Esophageal Variceal Bleeding After Endoscopic Variceal Ligation

Hemodynamic Changes and NOS2/VEGF Expression in Patients with Portal Hypertension

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Analysis of the Etiology of Portal Vein Thrombosis in Liver Cirrhosis Patients

The effect of TIPS on angiogenesis in esophagogastric tissue of patients with portal hypertension

The relationship of portal hemodynamics to nitric oxide and endothelin levels in patients with liver cirrhosis

Noninvasive Assessment of Portal Hypertension by Ultrasonography

The Alterations of Plasma ET-1 and NO Post Selective Pericardial Devascularization in Patients with Hepatic Portal Hypertension

A Study on the Sensitivity of Different Methods in the Diagnosis of Portal Hypertension Associated with Liver Cirrhosis

Relation Between Indexes of Portal Vein, Splenic Vein and G/S Staging in Chronic Viral Hepatitis

Serum Levels of Epinephrine and Norepinephrine in Cirrhotic Patients with Portal Hypertension.

Therapeutic effects of percutaneous transhepatic variceal embolization combined with partial splenic embolization for portal hypertention

Levels of Plasma Calcitonin Gene-Related Peptide and Endothelin in Liver Cirrhosis

Thrombelastogram monitoring in autologous blood transfusion during splenectomy in the treatment of portalhy pertension

Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction

Two Surgical Procedures for Esophagogastric Variceal Bleeding in Patients with Portal Hypertension

Research progress on signaling pathways in cirrhotic portal hypertension